Literature DB >> 20445049

Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors.

Kiren Ubhi1, Edward Rockenstein, Michael Mante, Chandra Inglis, Anthony Adame, Christina Patrick, Kristen Whitney, Eliezer Masliah.   

Abstract

Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by striatonigral degeneration and olivo-pontocerebellar atrophy. Neuronal degeneration is accompanied by primarily oligodendrocytic accumulation of alpha-synuclein (alphasyn) as opposed to the neuronal inclusions more commonly found in other alpha-synucleinopathies such as Parkinson's disease. It is unclear how alphasyn accumulation in oligodendrocytes may lead to the extensive neurodegeneration observed in MSA; we hypothesize that the altered expression of oligodendrocyte-derived neurotrophic factors by alphasyn may be involved. In this context, the expression of a number neurotrophic factors reportedly expressed by oligodendrocytes [glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), and insulin-like growth factor 1 (IGF-1), as well as basic fibroblast growth factor 2 (bFGF2), reportedly astrocyte derived] were examined in transgenic mouse models expressing human alphasyn (halphasyn) under the control of either neuronal (PDGFbeta or mThy1) or oligodendrocytic (MBP) promoters. Although protein levels of BDNF and IGF-1 were altered in all the alphasyn transgenic mice regardless of promoter type, a specific decrease in GDNF protein expression was observed in the MBP-halphasyn transgenic mice. Intracerebroventricular infusion of GDNF improved behavioral deficits and ameliorated neurodegenerative pathology in the MBP-halphasyn transgenic mice. Consistent with the studies in the MBP-halphasyn transgenic mice, analysis of GDNF expression levels in human MSA samples demonstrated a decrease in the white frontal cortex and to a lesser degree in the cerebellum compared with controls. These results suggest a mechanism in which alphasyn expression in oligodendrocytes impacts on the trophic support provided by these cells for neurons, perhaps contributing to neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20445049      PMCID: PMC2896284          DOI: 10.1523/JNEUROSCI.0567-10.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  73 in total

Review 1.  Oligodendrocytes as providers of growth factors.

Authors:  Yangzhou Du; Cheryl F Dreyfus
Journal:  J Neurosci Res       Date:  2002-06-15       Impact factor: 4.164

2.  Neuronal signals regulate neurotrophin expression in oligodendrocytes of the basal forebrain.

Authors:  X Dai; P Qu; C F Dreyfus
Journal:  Glia       Date:  2001-05       Impact factor: 7.452

Review 3.  New insights into brain BDNF function in normal aging and Alzheimer disease.

Authors:  Lucia Tapia-Arancibia; Esteban Aliaga; Michelle Silhol; Sandor Arancibia
Journal:  Brain Res Rev       Date:  2008-08-03

Review 4.  GDNF therapy for Parkinson's disease.

Authors:  Murray Hong; Karim Mukhida; Ivar Mendez
Journal:  Expert Rev Neurother       Date:  2008-07       Impact factor: 4.618

Review 5.  Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan.

Authors:  André Aleman; Ignacio Torres-Alemán
Journal:  Prog Neurobiol       Date:  2009-08-07       Impact factor: 11.685

Review 6.  A neurotrophic rationale for the therapy of neurodegenerative disorders.

Authors:  H Uri Saragovi; Edith Hamel; Adriana Di Polo
Journal:  Curr Alzheimer Res       Date:  2009-10       Impact factor: 3.498

7.  Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.

Authors:  John B Rose; Leslie Crews; Edward Rockenstein; Anthony Adame; Michael Mante; Louis B Hersh; Fred H Gage; Brian Spencer; Rewati Potkar; Robert A Marr; Eliezer Masliah
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

8.  Absolute requirement of GDNF for adult catecholaminergic neuron survival.

Authors:  Alberto Pascual; María Hidalgo-Figueroa; José I Piruat; C Oscar Pintado; Raquel Gómez-Díaz; José López-Barneo
Journal:  Nat Neurosci       Date:  2008-06-08       Impact factor: 24.884

9.  GDNF-secreting human neural progenitor cells increase tyrosine hydroxylase and VMAT2 expression in MPTP-treated cynomolgus monkeys.

Authors:  Marina E Emborg; Allison D Ebert; Jeff Moirano; Sun Peng; Masatoshi Suzuki; Elizabeth Capowski; Valerie Joers; Ben Z Roitberg; Patrick Aebischer; Clive N Svendsen
Journal:  Cell Transplant       Date:  2008       Impact factor: 4.064

10.  Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease.

Authors:  Ofer Sadan; Merav Bahat-Stromza; Yael Barhum; Yossef S Levy; Anat Pisnevsky; Hagit Peretz; Avihay Bar Ilan; Shlomo Bulvik; Noam Shemesh; Dana Krepel; Yoram Cohen; Eldad Melamed; Daniel Offen
Journal:  Stem Cells Dev       Date:  2009-10       Impact factor: 3.272

View more
  87 in total

Review 1.  Multiple system atrophy: a clinical and neuropathological perspective.

Authors:  Kiren Ubhi; Phillip Low; Eliezer Masliah
Journal:  Trends Neurosci       Date:  2011-09-29       Impact factor: 13.837

2.  Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.

Authors:  Kiren Ubhi; Chandra Inglis; Michael Mante; Christina Patrick; Anthony Adame; Brian Spencer; Edward Rockenstein; Verena May; Juergen Winkler; Eliezer Masliah
Journal:  Exp Neurol       Date:  2012-01-16       Impact factor: 5.330

3.  Neuronal to oligodendroglial α-synuclein redistribution in a double transgenic model of multiple system atrophy.

Authors:  Edward Rockenstein; Kiren Ubhi; Chandra Inglis; Michael Mante; Christina Patrick; Anthony Adame; Eliezer Masliah
Journal:  Neuroreport       Date:  2012-03-07       Impact factor: 1.837

4.  Insulin resistance and exendin-4 treatment for multiple system atrophy.

Authors:  Fares Bassil; Marie-Hélène Canron; Anne Vital; Erwan Bezard; Yazhou Li; Nigel H Greig; Seema Gulyani; Dimitrios Kapogiannis; Pierre-Olivier Fernagut; Wassilios G Meissner
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

5.  Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD.

Authors:  Silke Nuber; Daniel Tadros; Jerel Fields; Cassia Rose Overk; Benjamin Ettle; Kori Kosberg; Michael Mante; Edward Rockenstein; Margarita Trejo; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-08       Impact factor: 17.088

Review 6.  Novel therapeutic approaches in multiple system atrophy.

Authors:  Jose-Alberto Palma; Horacio Kaufmann
Journal:  Clin Auton Res       Date:  2014-06-14       Impact factor: 4.435

Review 7.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

8.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

Review 9.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

10.  Serine 421 regulates mutant huntingtin toxicity and clearance in mice.

Authors:  Ian H Kratter; Hengameh Zahed; Alice Lau; Andrey S Tsvetkov; Aaron C Daub; Kurt F Weiberth; Xiaofeng Gu; Frédéric Saudou; Sandrine Humbert; X William Yang; Alex Osmand; Joan S Steffan; Eliezer Masliah; Steven Finkbeiner
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.